• CardioDynamics (San Diego) reported on two studies which correlate BioZ with Ejection Fraction (EF) from echocardiography (echo). Researchers from Stanford Medical Center (Stanford, California), reported results of a pacemaker optimization study at the Heart Failure Society of America annual meeting. The study's purpose was to identify a method more suitable than echo for routine use in pacemaker optimization. Researchers compared ICG and echo both in terms of data quality and ease of use. The researchers concluded that the BioZ ICG provided more precise optimization of pacemaker patients than echo, and ICG had the added benefit of not requiring any manual measurement or subjective interpretation.

A new study presented at the annual meeting of the Diabetes Technology Society (Bethesda, Maryland) showed that changes in the position of a conventional insulin pump, relative to its infusion set, can significantly impact expected insulin delivery rates. Such changes may occur during routine daily activities such as getting dressed, sleeping or showering. This siphon effect has been reported previously in hospital IV pumps, but this is the first time it has been investigated in continuous subcutaneous insulin infusion pumps. The investigators reached this finding by quantifying the effect of hydrostatic pressure (the pressure exerted on a portion of a column of fluid as a result of the weight of the fluid above it) on insulin delivery during bolus dosages, basal rates and static changes in insulin pumps. They found that raising or lowering a conventional insulin pump, to the full extent of its tubing, can significantly affect the accuracy of insulin delivery, especially at low basal infusion rates.

• Medtronic (Minneapolis) reported the U.S. market launch of the Endeavor Sprint drug-eluting stent (DES) on a rapid exchange (RX) delivery system. Using the Sprinter balloon catheter technology, the Endeavor Sprint system puts the Endeavor DES on an enhanced delivery platform, making Medtronic's flagship DES even easier for physicians to deliver to the site of coronary blockages, the company said.

• Osteotech (Eatontown, New Jersey) said that its next-generation grafting material will be marketed under the brand name MagniFuse Bone Graft. MagniFuse is a combination of allograft bone within a polymer mesh that will provide targeted and contained delivery. The polymer mesh is made from a biodegradable suture material and is designed for effective cellular in-growth and complete resorption within three to six months, while not interfering with bone regeneration. The polymer mesh provides a controlled environment for proximate allograft interaction eliminating issues with graft site migration or irrigation that is often seen with currently available bone graft substitutes.

• Solos Endoscopy (Boston) said it has provided equipment to the Advanced Breast Center (ABC) in Puerto Rico for its Mammo View system. ABC requested the Mammo View system in order to promote breast health among women in Puerto Rico and aid in detecting early stages of breast cancer. Solos Endoscopy's Mammo View system uses advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts where the majority of breast cancers arise. The Mammo View contains versatile and customizable medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures.